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established lesional rats had autoantibodies specific for components 
of the hair follicle of which one had skeletal muscle autoantibodies 
and four had antinuclear antibodies. For autoantibodies against the 
inner root sheath in some active lesional rats, sera could be titrated 
to 1:1280 and still maintain staining intensity. Control sera from 
PVG/Ola rats showed no positive staining for hair-follicle compo­
nents or other tissues. 
An earlier study by Michie, t which stimulated the current work, 
detected autoantibody activity in DEBR serum with staining of hair 
cuticle and fiber. Using sera from AA patients Calver et a/* reported 
staining for the outer root sheath, inner root sheath, hair shaft, 
epidermis, sebaceous glands, and apocrine glands, with individual 
sera exhibiting heterogeneity in autoantibody specificity. Our 
findings revealed a more restricted range of epithelial targets in the 
DEBR rat. The autoantibodies raised in the DEBR rat were against 
normally expressed antigens as they were able to target epithelia in 
normal PVG/Ola rat tissue as well as lesional DEBR follicles. Nor 
were the autoantibodies species specific as they targeted the same 
epithelia in human scalp sections. 
Autoantibodies against striated muscle were particularly promi­
nent in serum from prelesional rats. Cell antinuclear antibodies as 
found in 10 of the 30 DEBR rat sera when tested on a rat embryonic 
epidermal cell line were further characterized as staining for 
nucleoli, centrosomes, centromeres, and nuclear lamina or pre­
sented as a homogeneous nuclear stain. Autoantibodies against 
other tissues were not detected. When considering all types of 
t Michie HJ: The DEBR rat: an animal model of human alopecia areata. 
Thesis, University of Dundee. 1989. 
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autoantibodies, nine of ten prelesional DEBR rats expressed some 
form of autoantibody at a serum dilution of 1:80. 
Our findings clearly show that in the DEBR model, as in human 
AA, the immune system can be presented with a range of poten­
tially stimulatory self antigens derived from hair-follicle epidermal 
differentia. Because the production of antibody seemed to coincide 
with the development of the cellular infiltrate and there was 
variable targeting of a range of follicle dilferentia, autoantibodies in 
DEBR serum may be a consequence of cellular disruption by 
immune cells and subsequent release of autoantigens. This presence 
of autoantibodies ahead of actual hair loss could indicate their 
production and possible active participation in the progression of 
the lesion. 
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Topical Immunotherapy in Children with 
Alopecia Areata 
Giovanni Orecchia and Piergiorgio Malagoli 
Department of Dermatology, University of Pavia, Pavia, Italy 
I
n the last decade in Europe, topical squaric acid dibutylester 
( SADBE) has been used in the treatment of alopecia areata 
in the adult population. This study attempts to define this 
drug's effectiveness and handiness in pediatric patients suf­
fering from severe alopecia areata, who are psychologically 
disturbed and resistant to other therapies. 
Twenty-eight children (under 13 years old), suffering from 
extensive and long-standing alopecia areata and who were not 
responsive to conventional therapies, were sensitized on the head 
with 2% of SADBE in acetone and treated with weekly applica­
tions. The treatment lasted 12 months. In nine patients (32.1%) 
Reprint requests to: Dr. G. Orecchia. Clinica Dermatologica, Policlinico 
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Abbreviation: SADBE. squaric acid dibutylester. 
complete or cosmetically acceptable regrowth was achieved and in 
another six (21.4"Ic,) a significant hair regrowth appeared. No 
correlation was found between response and sex, age of onset of the 
illness, extent, duration, and dilferent clinical types of the disease. 
Fourteen of28 patients were followed up for a period ranging from 
18 months to 8 years: even if SADBE is not a cure for alopecia, it 
remained efficacious in relapses, too. 
In severe forms of AA, under psycologic disturbed personal and 
family situations [1 , treatment with SADBE seems justified for 
children, too. Indeed, particularly in these patients, it has many 
advantages compared with other therapies that are either associated 
with serious side effects or, in the judgment of some authors, 
ineffective: it is a topical treatment, it is easy to apply (home therapy), 
and furthermore it is readily accepted because it is a clean therapy 
(unlike topical anthralin). In addition it is not time consuming (there is 
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a check-up every 2 months) and it is neither painful (unlike intrale­
sional infiltration with triamcinolone) nor risky [2] (unlike some 
potent topical corticosteroids, which may cause systemic absorption, 
adrenal suppression, and retardation of bone growth). 
This work demonstrates also that any adverse effect of this therapy 
can be avoided as applications are carried out weekly, with very low 
concentrations, over less than 5% of the body area, in a site, the head, 
which is quite tolerant to topical allergens. Because irritation is not a 
prerequisite of recovery, we believe that SADBE is a suitable treatment 
even for children resistant to other therapies [3-5]. 
Therefore, considering the advantages due to its easy application 
and to the absence of side effects, we attest to the validity of SADBE 
as a suitable treatment particularly apt in children resistant to 
conventional therapies. 
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T
opical diphenylcyclopropenone and minoxidil have 
been used in the treatment of alopecia areata with 
variable results [1-5]. 
This study was designed to evaluate the efficacy of 
diphenylcyclopropenone alone or in combination 
with topical 5% minoxidil for the treatment of chronic severe 
alopecia areata. The effect of therapy on cutuaneous T-cell and 
Langerhans cell subpopulations and intercellular adhesions molc­
cule-1 expression was also examined. 
Fifteen patients with chronic (more than 2 years), severe (more 
than 50% scalp involvement) alopecia areata participated in a 
24-week trial. Half of the scalp was treated with diphenylcyclopro­
penone once weekly and with either 5% minoxidil solution or a 
vehicle solution twice daily in a randomized double-blind design. 
Skin biopsy specimens from each half of the scalp were obtained 
before therapy and after 12 and 24 weeks of therapy for histologic 
immunophenotypic analysis. 
Thirteen patients completed the study. Five of the 13 patients 
(38%) showed marked regrowth of coarse terminal hair after 24 
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weeks of treatment with DPCP. The addition of topical 5% 
minoxidil did not produce any significant clinical benefit in this 
24-week trial. Immunophenotypic analysis showed no differ­
ences between responders and nonresponders at baseline. 
During treatment, Leu-4, Leu-2, and Leu-3 and keratinocyte 
intercellular adhesion molecule 1 expression were signifi­
cantly reduced in biopsy specimens of responders versus non­
responders. 
Diphenylcyclopropenone treatment showed a 38% success rate in 
producing cosmetically acceptable regrowth in patients with 
chronic severe alopecia. 
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